Properties of different pancreatin preparations used in pancreatic exocrine insufficiency

@article{Lhr2009PropertiesOD,
  title={Properties of different pancreatin preparations used in pancreatic exocrine insufficiency},
  author={Johannes Matthias L{\"o}hr and Frank Hummel and Konstantinos T Pirilis and Gregor Steinkamp and Andrea K{\"o}rner and Friederike Henniges},
  journal={European Journal of Gastroenterology \& Hepatology},
  year={2009},
  volume={21},
  pages={1024-1031}
}
Background Pancreatic enzyme preparations are a life-saving substitution for a pivotal physiological function of the entire organism that is impaired in chronic pancreatitis, cystic fibrosis and other diseases with exocrine pancreatic insufficiency. Pancreatic enzyme preparations, generically called pancreatin, are not alike. Rather, they present a broad variety of pancreatin composition. Aim The properties of a set of commercially available pancreatin preparations were investigated in light of… Expand
Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS
TLDR
Pancreatic enzyme-replacement therapy (PERT), provided as pancreatin to patients with pancreatic exocrine insufficiency, is considered an essential substitute for the pivotal physiological function the pancreas fulfills in digestion, but preparations available in Russia and CIS demonstrate product- to-product and batch-to-batch variability regarding the measured properties of lipase activity, dissolution, and particle size. Expand
Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency
TLDR
Three novel ciliate lipases derived from Tetrahymena thermophila are cloned and analyzed and are promising candidates for an improved enzyme replacement therapy for exocrine pancreatic insufficiency. Expand
In vitro Comparison of Pancreatic Enzyme Preparations Available in the Indian Market
TLDR
Differences exist between pancreatic enzyme preparations in terms of physical properties, dissolution, and release behavior that can affect their clinical efficacy, and the present study suggests that these preparations should not be used interchangeably. Expand
In vitro comparative studies on pancreatic enzyme preparations
  • J. Löhr
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 2010
TLDR
The pathophysiology of pancreatic exocrine insufficiency (PEI) must be taken into account, and clinically proven products such as Creon (Solvay Pharmaceuticals, Hannover, Germany) are inferior. Expand
Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.
TLDR
Approaches for improving the results of enzyme therapy are described including changing to, or adding, a different product, adding non-enteric coated enzymes, use of antisecretory drugs and/or antacids, and changing the timing of enzyme administration. Expand
Pancreatic enzyme therapy.
TLDR
There is still no simple test that can be used to diagnose pancreatic exocrine insufficiency with certainty, and the treatment is symptomatic; its goals are to lessen steatorrhea and reverse weight loss. Expand
Diagnosis and treatment of pancreatic exocrine insufficiency.
TLDR
Methods evaluating digestion, such as fecal fat quantification and the (13)C-mixed triglycerides test, are the most accurate tests for pancreatic exocrine insufficiency, but the probability of the diagnosis can also be estimated based on symptoms, signs of malnutrition in blood tests, fecal elastase 1 levels and signs of morphologically severe chronic pancreatitis on imaging. Expand
Role of Acid Suppression in Exocrine Pancreatic Insufficiency: A Therapeutic Principle
The use of acid suppression in patients with exocrine pancreatic insufficiency (EPI) additionally to enteric-coated pancreatic enzyme preparations (PEPs) is controversial. In current recommendations,Expand
Response to: properties of different pancreatin preparations used in pancreatic exocrine insufficiency, Löhr JM et al. Eur J Gastroenterol Hepatol 2009; 21(9):1024-1031.
  • P. Lederer
  • Medicine
  • European journal of gastroenterology & hepatology
  • 2010
TLDR
Comparing the particle sizes of 10 different pancreatin preparations indicated that approximately 90% of Kreon microspheres (Solvay Pharmaceuticals, Hannover, Germany) have a diameter less than 1.7 mm promote suboptimal digestion in patients with pancreatic insufficiency (PI). Expand
Comparative efficiency of microbial enzyme preparations versus pancreatin for in vitro alimentary protein digestion
TLDR
Although the efficiency of these microbial preparations to increase the rate of absorption of nitrogen-containing compounds in severe pancreatic insufficiency remains to be tested in vivo, in vitro data indicate proteolytic capacities of such preparations for alimentary protein digestion. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Therapy of pancreatogenic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage?
TLDR
It is concluded that therapy with acid-protected pancreatin may simplify and improve treatment of exocrine pancreatic insufficiency in the presence of gastric hyper- or normo-acidity. Expand
Pancreatin preparations used in the treatment of cystic fibrosis‐‐ lipase content and in vitro release.
TLDR
The results show some factors contributing to variable clinical responses to pancreatic supplements are shown and improvements may result if a patient is assessed on different preparations. Expand
Pancreatic enzyme therapy for pancreatic exocrine insufficiency
TLDR
The present article critically reviews current therapeutic approaches to pancreatic exocrine insufficiency and recommends enzymes in the form of enteric-coated minimicrospheres to avoid acid-mediated lipase inactivation and ensures gastric emptying of enzymes in parallel with nutrients. Expand
Enzyme Content and Acid Stability of Enteric-Coated Pancreatic Enzyme Products In Vitro
TLDR
While assay of pancreatic enzymes reveal they were equal to their USP claims regarding their enzyme content, not all pancreatic enzyme replacements are equal in their release of lipase activity according to USP requirements. Expand
Pancreatic enzyme supplementation therapy
TLDR
In the compliant patient, diagnosis of pancreatic exocrine insufficiency needs to be reviewed, particularly cases of celiac disease, (concomitant) bacterial overgrowth, and blind loop syndrome, as well as giardiasis, which need to be excluded or otherwise be treated specifically. Expand
Pancreatic enzyme replacement therapy in post-pancreatectomy patients.
  • M. Braga, M. Cristallo, +5 authors V. Di Carlo
  • Medicine
  • International journal of pancreatology : official journal of the International Association of Pancreatology
  • 1989
TLDR
The complete loss of exocrine pancreatic function following surgery was well tolerated and when patients were on pancrelipase therapy, much of the original body weight was recovered and the biochemical indices of malnutrition were normalized. Expand
Lipase Supplementation Therapy: Standards, Alternatives, and Perspectives
TLDR
The pathophysiologic characteristics of pancreatic exocrine insufficiency, prerequisites for use of alternative lipase sources as well as currently available lipases of nonporcine origin, and new developments are discussed. Expand
Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency.
TLDR
Patients with chronic pancreatitis and exocrine pancreatic insufficiency ingested a test meal including colloidal 99m‐technetium‐radiolabelled liver pate and swallowed two pancreatin capsules, in which half of the granules had been replaced with 111‐indium‐ radiolabelling plastic particles of comparable physical dimensions. Expand
[Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity].
TLDR
Ten patients with exocrine pancreatic insufficiency received two types of enzyme substitution (Kreon) and were investigated using the cholesterol-14C-octanoate breath test, showing an obvious delay in intraduodenal lipolytic activity using the 1.0-1.2 mm preparation. Expand
Altered postprandial motility in chronic pancreatitis: role of malabsorption.
TLDR
In subjects with pancreatic insufficiency, a low-energy liquid meal induces shorter fed motor pattern associated with accelerated gastric emptying and intestinal transitCompared with healthy subjects, ileal delivery of malabsorbed chyme may be involved as a mechanism. Expand
...
1
2
3
4
5
...